Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Sartorius AG
  6. News
  7. Summary
    SRT   DE0007165607


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Waters and Sartorius Partner to Help Bioprocess Scientists...

10/27/2021 | 11:48am EST

Waters Corporation (NYSE: WAT) and Sartorius (DAX: SRT:GR) announced today they will partner to provide bioprocess experts with direct access to high-quality mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development. Sartorius and Waters will partner to implement the BioAccord™ LC-MS System from Waters as a new bioprocess analyzer with data connectivity to Sartorius' Ambr® multi-parallel bioreactor systems to deliver mass spectral information on drug substances, related analytes and cell culture media. This combination will greatly accelerate and improve the accuracy and speed of tasks from clone selection to bioprocess optimization.

At a ~10% CAGR from 2020 to 2025, biopharmaceuticals is the fastest-growing segment of the overall pharmaceutical market, according to a report by Evaluate Pharma. Fueling this growth is the unprecedented rate at which highly complex new biologics are coming to market. As a consequence, biopharmaceutical manufacturers are requiring more upstream analytical data than ever about drug product attributes and bioprocessing efficiency to enable the development of new, better, and more affordable medicines.

"Waters and Sartorius share a commitment to biopharmaceutical customers to solve their problems with the very best process and analytical tools," said Davy Petit, Senior Director of Global Pharmaceutical and Biomedical Research Business, Waters Corporation. "Clone selection and process development can benefit significantly from at-line versatile mass spectrometry data which can help bioprocess engineers accelerate workflows and increase confidence in making critical decisions. The combination of our technology in the hands of bioprocess scientists, alongside the well-established Sartorius Ambr bioreactor systems installed-base, can significantly reduce the development timeline for delivery of medicines and vaccines."

"The combination of Ambr and the easy-to-use at-line Waters BioAccord LC-MS System will save bioprocess scientists substantial time and accelerate clone selection and upstream process development," said Mario Becker, Head of Product Management Cell Culture Technologies at Sartorius. "The closer we can bring fundamentally important MS data to the point where it is needed, and the more Ambr samples that can be tested for quality attributes, the better we can provide bioprocess scientists a more complete picture of drug product quality at any point during cell-line, media, and process development. Eventually, we can envisage such process control, monitoring and product quality testing being fully integrated into the manufacturing environment."

Fast Access to Mass Spectrometry Data for Those Who Are Not Mass Spec Experts

Biological drugs are made by living cells in bioreactors like the Sartorius Ambr high throughput bioreactor system. At the conclusion of the cell culture process, the proteins are separated from the cell residue and samples are sent to a central laboratory to await testing by analytical scientists using specialist liquid chromatography-mass spectrometry (LC-MS) instruments. It's not uncommon for the process to stretch across 2-4 weeks or more depending on the workload, equipment availability, priorities, and staffing levels of the central analytical laboratory.

The combined offering from Sartorius and Waters aims to shorten the process from what can take over a month to two days or less, while giving more control to bioprocess scientists to obtain robust mass spectrometry data for drug substance and cell culture media samples. The industry-leading range of Sartorius Ambr multi-parallel bioreactors has been developed to take scientists through the early steps of their upstream process from cell selection, through to process optimization. The Waters BioAccord System is a small footprint LC-MS instrument designed as an easy-to-operate, at-line benchtop bioprocess analyzer. Its pre-defined analytical methods, guided workflows, auto-calibration, and auto-tuning features allow those without any mass spectrometry experience to obtain high-quality mass spectral data within minutes.


Interested customers can contact both Waters and Sartorius:

  • Waters Corporation contact: John_Gebler@waters.com
  • Sartorius contact: Ian.Ransome@Sartorius.com
Additional Resources

Learn more about the Sartorius-Waters collaboration

Learn more about the Waters BioAccord System with ACQUITY Premier

Learn more about Sartorius Ambr multi-parallel bioreactor systems


Sartorius AG published this content on 27 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 October 2021 15:47:04 UTC.

ę Publicnow 2021
All news about SARTORIUS AG
04:24aSartorius to Pay $11.3 Million COVID-19 Bonus to Employees
03:42aSARTORIUS : employees to receive a bonus for their commitment and...
11/26Sartorius to Invest EUR100 Million in France by 2025, Create Up to 400 Jobs
11/25Sartorius to Invest Around EUR270 Million in South Korea Expansion
11/24Sartorius Significantly Expands Activities in South Korea
11/18SARTORIUS : Opens Cell Culture Technology Center
11/12SARTORIUS VORZUEGE : DZ Bank reiterates its Neutral rating
11/11SARTORIUS VORZUEGE : Gets a Sell rating from UBS
11/03Sartorius Honored as “Overall Best Bioprocessing Supplier” Award...
11/01Sartorius Introduces Faster, Higher Capacity Sartolab« RF|BT...
More news
Analyst Recommendations on SARTORIUS AG
More recommendations
Sales 2021 3 394 M 3 831 M 3 831 M
Net income 2021 411 M 464 M 464 M
Net Debt 2021 1 885 M 2 128 M 2 128 M
P/E ratio 2021 83,2x
Yield 2021 0,27%
Capitalization 36 464 M 41 235 M 41 165 M
EV / Sales 2021 11,3x
EV / Sales 2022 9,94x
Nbr of Employees 12 952
Free-Float 35,0%
Duration : Period :
Sartorius AG Technical Analysis Chart | SRT | DE0007165607 | MarketScreener
Technical analysis trends SARTORIUS AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 495,00 €
Average target price 483,55 €
Spread / Average Target -2,31%
EPS Revisions
Managers and Directors
Joachim Kreuzburg Chief Executive Officer
Rainer Lehmann Chief Financial Officer
Lothar Kappich Chairman-Supervisory Board
Oscar-Werner Reif Head-Research & Development
Volker Niebel Head-Production, Procurement & Business Operations
Sector and Competitors
1st jan.Capi. (M$)
SARTORIUS AG43.48%41 235
BIOTAGE AB (PUBL)88.49%1 912
908 DEVICES INC.-57.30%679